Graybug Vision, Inc. (NASDAQ:GRAY – Get Free Report) shares were down 3.3% on Friday . The company traded as low as $2.01 and last traded at $2.04. Approximately 35,965 shares changed hands during mid-day trading, an increase of 1,561% from the average daily volume of 2,165 shares. The stock had previously closed at $2.11.
Graybug Vision Stock Performance
The firm has a market cap of $3.20 million, a price-to-earnings ratio of -1.18 and a beta of 1.20. The business has a fifty day moving average of $2.50 and a two-hundred day moving average of $3.29.
About Graybug Vision
Graybug Vision, Inc, a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.
Further Reading
- Five stocks we like better than Graybug Vision
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- FedEx Delivers Another Crushing Blow to Its Stock Price
- P/E Ratio Calculation: How to Assess Stocks
- Analysts Stay Bullish on Rocket Lab as Signs of a Bottom Emerge
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Micron Stock Will Retest All-Time Highs This Year
Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.
